Answers are grounded in this paper and cite their sources.
Anal cancer incidence is increasing among men who have sex with men (MSM) living with HIV, driven by persistent high-risk (HR) HPV infection. HPV mRNA testing may offer higher specificity for detecting high-grade squamous intraepithelial lesions (HSIL) than cytology or HPV DNA testing, with potential economic implications. We evaluated the cost-effectiveness of screening strategies combining HPV biomarkers and post-high-resolution anoscopy (HRA) management. A Markov model simulated a cohort of MSM living with HIV to assess 45 screening strategies varying by algorithm (cytology, co-testing, HPV reflex), HPV assay (DNA-hybridization, DNA-PCR, mRNA), and post-HRA management (follow-up, infrared coagulation [IRC], trichloroacetic acid [TCA]). Outcomes included HSIL and anal cancer cases, quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). Strategies involving treatment reduced anal cancer incidence by 43–69% compared with no screening, with greater reductions for co-testing. Cytology was the most cost-effective option at €25 per test. At €6, co-testing became competitive, particularly with HR-HPV assays—DNA-hybridization (€13,203/QALY) and mRNA (€14,482/QALY). All optimal strategies included TCA. Anal cancer screening in MSM living with HIV is effective and cost-effective. Co-testing with cytology and HR-HPV assays—whether DNA or mRNA—combined with post-HRA treatment provided the greatest health benefits, while its cost-effectiveness depended strongly on HPV test cost and became favorable at lower HPV test costs. HPV mRNA-based approaches provided a comparable and viable alternative to HPV DNA.
No takes yet. Share an insight, caveat, or question.
Díaz et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: